Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 531-539

  Hedner, Ulla ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

EID: 0032725116     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615876     Document Type: Conference Paper

References (67)

1. Hoyer WL. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White II GC, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995; 35-45.
2. Nilsson IM and Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol. 1976;16:369-382.
3. Nilsson IM, Berntorp E, Zetterwall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med. 1988;328:947-950.
4. Hedner U, Tengborn L. Management of haemophilia A with antibodies: The effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide. Thromb Haemost. 1985;54:776-779.
5. Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood. 1971;37:381-387.
6. Hedner U, Nilsson IM. Induced tolerance in hemophilia patients with antibodies against IX:C. Acta Med Scand. 1983;214:191-197.
7. Colvin BT. Role of plasma-exchange in the management of patients with factor VIII inhibitors. La Ricerca Clin Lab. 1983;13:85-93.
8. Révész T, Mátyus J, Goldschmidt B, Harsanyi V. Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors. Arch Dis Child. 1980;55:641-643.
9. Nilsson IM, Jonsson S, Sundqvist S-B, Ahlberg A, Bergentz SE. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: Substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood. 1981;58:38-43.
10. Theodorsson B, Hedner U, Nilsson IM, Kisiel W. A technique for specific removal of factor IX alloantibodies from human plasma: Partial characterization of the alloantibodies. Blood. 1983;61:973-981.
11. Macik BG. Treatment of factor VIII inhibitors: Products and strategies. Semin Thromb Hemost. 1993;19:13-24.
12. Nilsson IM, Berntorp E, Zettervall O, Dahlback B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood. 1990;75:378-383.
13. Brackman HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1977;2:933.
14. Brackman HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res. 1986;150:180-195.
15. Gomperts ED, Jordan S, Church JA, Sakai R, Lemire J. Induction of tolerance to factor VIII in a child with a high-titer inhibitor: In vitro and in vivo observations. J Pediatr. 1984;104:70-75.
16. White GC, Taylor RE, Blatt PM, Roberts HR. Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: Report of a case. Blood. 1983;58:141.
17. Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost. 1987;58:1049-1052.
18. Sultan Y, White GC, Aronstam A, et al. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Nouv Rev Fr Hematol. 1986;28:85-89.
19. Mauser-Bunschoten EP, Niewenhuis HK. Rosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86:983-988.
20. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance of factor VIII in hemophiliacs with inhibitors. JAMA. 1988;259:65-68.
21. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia. Principal results from the international registry. Thromb Haemost. 1994;72:155-158.
22. Warrier I and Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis. 1998;9:S125-S128.
23. Brettler DB, Forsberg MS, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMIllan C, Roberts H. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII: A multicenter U.S. experience. Arch Intern Med. 1989;149:1381-1385.
24. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex versus proplex: A controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135-1138.
25. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sizma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med. 1981;305:717-721.
26. Hultin MB. Activated clotting factors in factor IX concentrates. Blood. 1979;54:1028-1038.
27. White GC II, Roberts HR, Kindon HS, Lundblad RL. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood. 1977;49:159-170.
28. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3-5.
29. Fekete L, Holst S, Peetoom F, et al. 'Auto' factor IX concentrate: A new therapeutic approach to treatment of hemophilia A patients with inhibitors. Paper presented at the XIV International Congress of Hematology, 1972.
30. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt, PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies for factor VIII. A multicentre trial. N Engl J Med. 1980;303:421-425.
31. Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrate and persistence in the circulation after infusion. Blood. 1979;53:828-837.
32. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Art Thromb. 1992;12:1111-1121.
33. Kasper CK, Feinstein DI. Rising factor VIII inhibitor titers after Konyne factor IX complex. N Engl J Med. 1976;295:505-506.
34. Rauch U, Bonderman D, Badimon J, et al. Platelets become tissue factor positive during thrombus formation. Blood. 1998;92:347a.
35. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina." Thromb Haemost. 1995;74:7-17.
36. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res. 1996;83:307-320.
37. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76:731-736.
38. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis. 1990;1:307-317.
39. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.
40. Le DT, Borgs P, Toneff W, Witte MH, Rapaport SI. Hemostatic factors in rabbit limb lymph: Relationship to mechanism regulating extravascular coagulation. Am J Physiol. 1998;274:H769-H776.
41. Dvorak HN, Senger DR, Dvorak AM, Harey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227:1059-1061.
42. Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant factor VIIa. In: Aledort SM, Hoyer LW, Lusher JM, Reisner HM, White II GC, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:163-174.
43. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119-128.
44. Rao LVM, Rapaport SI Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood. 1993;81:2600-2607.
45. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIA (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912-918.
46. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973-978.
47. Hedner U, Glazer S Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H. Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet. 1988;ii:1193.
48. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Hemostasis. 1991;21:1-4.
49. Hedner U, Ingerslev J. Clinical use of recombinant FVIIA (rFVIIA). Transfus Sci. 1998;19:163-176.
50. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIA (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;70:773-778.
51. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, Heim M, Martinowitz U. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996;75:432-436.
52. Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery. Eur J Haematol. 1998;61(Suppl 63):15-17.
53. Ingram GI, Dykes SR, Crese AL, Mellor P, Swan AV, Kaufert JK, Rizza CR, Spooner RJ, Biggs R. Home treatment in hemophilia: Clinical, social and economic advantages. Clin Lab Haematol. 1979;1:13-27.
54. Stein SF, Duncan A, Cutler D, et al. DIC in a hemophiliac treated with recombinant factor VIIa. Blood. 1990;76:438a.
55. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIA. Haemostasis. 1996;26(Suppl 1):118-123.
56. Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res. 1996;81:533-543.
57. rd International Congress of the World Federation of Hemophilia. The Hague, The Netherlands, May 17-21, 1998.
58. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol. 1994;1:471-478.
59. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734-744.
60. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis. 1996;26(Suppl 1):102-108.
61. Molskov Bech R. Personal communication, 1998.
62. Beguin S, Keularts I. On the coagulation of platelet rich plasma. Physiological mechanism and pharmacological consequences. In: Lecture Book: 15th International Congress on Thormbosis, October 16-21, 1998; 97-101.
63. Hoffman M, Monroe DM, Oliver JA, et al. Factor IXa and Xa play distinct roles in tissue factor -dependent initiation of coagulation. Blood. 1995; 86:1794-1801.
64. Hansen LL, Nielsen FE, Hedner U. Validation of method for determination of recombinant FVIIa coagulant activity in plasma using a one-stage clotting assay. Thromb Haemostas. 1993; 69:865.
65. Nicolaisen EM, Hansen LL, Poulsen F, et al. Immunological aspects of recombinant factor VIIa(rFVIIa) in clinical use. Thromb Haemostas. 1996; 76:200-204.
66. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. 1992;80:25-28.
67. Revesz, Arets B, Bierings M, et al. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemostas. 1998;80:353.